European Archives - Page 291 of 1177 - European Medical Journal

Does Immunosuppressive Therapy Increase Infection Risk in Older Adults with IBD?

New research from DDW 2024 shows older adults with inflammatory bowel disease treated with advanced therapies may face a slightly increased risk of infection.

Surgery Versus GLP-1 Agonists in Patients with Obesity and Kidney Disease

Metabolic bariatric surgery offers substantial protective benefits for patients with chronic kidney disease, Type 2 diabetes, and obesity, according to new research.

Time-Restricted Eating Improves Glycaemic Control in Adults at Risk of Type 2 Diabetes: EASD 2024

Time-restricted eating, limiting food intake to an 8-hour window, significantly improves blood sugar control in adults at risk of Type 2 diabetes, research from EASD 2024 shows.

Liraglutide Effective for Children with Obesity Aged Under 12 Years: EASD 2024

The SCALE Kids trial has found that weight-loss drug liraglutide is safe and effective for children aged 6 to under 12 years living with obesity.

Breast Cancer Risk After Bariatric Surgery

In a new, nonrandomised controlled trial, researchers have found that breast cancer risk was lower in individuals who had undergone bariatric surgery.

The ITP Treatment Landscape

The limitations of currently available therapies for immune thrombocytopenia (ITP) mean that long-term responses are difficult to maintain…

EMJ Hematology 12 [Supplement 4] 2024

The limitations of currently available therapies for immune thrombocytopenia (ITP) mean that long-term responses are difficult to maintain…

Answering the Patient’s Call: A Move Towards Personalized Primary Biliary Cholangitis Care

The key to personalized care for patients with primary biliary cholangitis (PBC) starts with good and effective dialogue between the…

Season 7 highlights: GOLD Medal Moments

The new season of the podcast is only a week away, so before we get started – why not have a listen to some of the best bits from Series 7?

Study Finds New Factors Associated with Lower Liver Cancer Risk

Declines in serum hepatitis B virus RNA during the first and second year of treatment with nucleoside analogues could be indicators of reduced risk for hepatocellular carcinoma.